Cancer of the Pancreas Screening Study (CAPS 3)

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Pancreatic NeoplasmPeutz-Jeghers Syndrome
Interventions
PROCEDURE

Biopsy, Fine Needle Aspiration (FNA)

If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.

DRUG

Secretin (human synthetic) - ChiRhoClin

Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

Lustgarten Foundation

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Johns Hopkins University

OTHER

NCT00438906 - Cancer of the Pancreas Screening Study (CAPS 3) | Biotech Hunter | Biotech Hunter